Literature DB >> 29273482

A novel host-protein assay outperforms routine parameters for distinguishing between bacterial and viral lower respiratory tract infections.

Michal Stein1, Shelly Lipman-Arens2, Kfir Oved3, Asi Cohen3, Ellen Bamberger4, Roy Navon3, Olga Boico3, Tom Friedman5, Liat Etshtein3, Meital Paz3, Tanya M Gottlieb3, Or Kriger2, Yura Fonar6, Ester Pri-Or3, Renata Yacobov2, Yaniv Dotan7, Amit Hochberg2, Moti Grupper7, Irina Chistyakov7, Israel Potasman7, Isaac Srugo7, Eran Eden3, Adi Klein2.   

Abstract

Bacterial and viral lower respiratory tract infections (LRTIs) are often clinically indistinguishable, leading to antibiotic overuse. We compared the diagnostic accuracy of a new assay that combines 3 host-biomarkers (TRAIL, IP-10, CRP) with parameters in routine use to distinguish bacterial from viral LRTIs. Study cohort included 184 potentially eligible pediatric and adult patients. Reference standard diagnosis was based on adjudication by an expert panel following comprehensive clinical and laboratory investigation (including respiratory PCRs). Experts were blinded to assay results and assay performers were blinded to reference standard outcomes. Evaluated cohort included 88 bacterial and 36 viral patients (23 did not fulfill inclusion criteria; 37 had indeterminate reference standard outcome). Assay distinguished bacterial from viral LRTI patients with sensitivity of 0.93±0.06 and specificity of 0.91±0.09, outperforming routine parameters, including WBC, CRP and chest x-ray signs. These findings support the assay's potential to help clinicians avoid missing bacterial LRTIs or overusing antibiotics. Published by Elsevier Inc.

Entities:  

Keywords:  Antibiotics; Biomarkers; Diagnostics; Host-immune response; LRTI; Pneumonia

Mesh:

Substances:

Year:  2017        PMID: 29273482     DOI: 10.1016/j.diagmicrobio.2017.11.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study.

Authors:  Liat Ashkenazi-Hoffnung; Kfir Oved; Roy Navon; Tom Friedman; Olga Boico; Meital Paz; Gali Kronenfeld; Liat Etshtein; Asi Cohen; Tanya M Gottlieb; Eran Eden; Irina Chistyakov; Isaac Srugo; Adi Klein; Shai Ashkenazi; Oded Scheuerman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-26       Impact factor: 3.267

Review 2.  FebriDx®: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections.

Authors:  Matt Shirley
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.476

3.  Potential of Internet of Medical Things (IoMT) applications in building a smart healthcare system: A systematic review.

Authors:  Ruby Dwivedi; Divya Mehrotra; Shaleen Chandra
Journal:  J Oral Biol Craniofac Res       Date:  2021-12-11

4.  A comparison of host response strategies to distinguish bacterial and viral infection.

Authors:  Melissa Ross; Ricardo Henao; Thomas W Burke; Emily R Ko; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.752

5.  The diagnostic value of nasal microbiota and clinical parameters in a multi-parametric prediction model to differentiate bacterial versus viral infections in lower respiratory tract infections.

Authors:  Yunlei Li; Chantal B van Houten; Stefan A Boers; Ruud Jansen; Asi Cohen; Dan Engelhard; Robert Kraaij; Saskia D Hiltemann; Jie Ju; David Fernández; Cristian Mankoc; Eva González; Wouter J de Waal; Karin M de Winter-de Groot; Tom F W Wolfs; Pieter Meijers; Bart Luijk; Jan Jelrik Oosterheert; Sanjay U C Sankatsing; Aik W J Bossink; Michal Stein; Adi Klein; Jalal Ashkar; Ellen Bamberger; Isaac Srugo; Majed Odeh; Yaniv Dotan; Olga Boico; Liat Etshtein; Meital Paz; Roy Navon; Tom Friedman; Einav Simon; Tanya M Gottlieb; Ester Pri-Or; Gali Kronenfeld; Kfir Oved; Eran Eden; Andrew P Stubbs; Louis J Bont; John P Hays
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.